Jubilant Ingrevia Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹1,051Cr
- −0.6% YoY
- −6.2% QoQ
- Net profit
- ₹47Cr
- −31.9% YoY
- −31.9% QoQ
- Margin
- 12%
- −1 pp YoY
- 0 pp QoQ
Guidance rank: #25 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
Specialty Chemicals volume growth has been double-digit over the past years, expected to continue. Specialty Chemicals segment aims for at least 20% CAGR EBITDA growth over a multi-year horizon, maintaining stable EBITDA margins around 25-26%.
From Jubilant Ingrevia Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Specialty Chemicals volume growth has been double-digit over the past years, expected to continue.
- Pricing has bottomed out recently, with signs of marginal price increases in some segments.
- FY '27 is considered a pivotal year to fill new capacity, including the new CDMO agro plant, with significant volume growth expected.
- 16 molecules confirmed with peak potential of INR1,400 crore; 80+ molecules in pipeline, implying future revenue growth over 3-4 years.
- Nutritional & Health Solutions showed volume growth; cosmetic grade and food grade products maintain steady growth.
- CDMO agro project shipment to start March 2026, with scaling expected in FY '27 and beyond.
2 more points from Jubilant Ingrevia Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jubilant Ingrevia Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Year-to-date capex of INR366 crore primarily spent on the upcoming CDMO agro plant at Bharuch and new multipurpose facility at Gajraula.
- Planned capex of approximately INR500 crore in FY 2027, funded mainly through internal accruals.
- Commissioned a new boiler at Bharuch site in Q3 FY '26 to enhance operational efficiency.
- Agro innovator project commissioning on track, expected to start dispatching volumes from March 2026.
- Construction commenced on a new multipurpose plant at Gajraula to add flexibility and capacity to CDMO and fine chemicals portfolio.
2 more points from Jubilant Ingrevia Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Ingrevia Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Jubilant Ingrevia has an expanded opportunity funnel of over 100 active CDMO opportunities with a peak annual revenue potential of approximately INR 3,500 crore.
- In the past year, more than 16 molecules have been confirmed with an estimated peak potential of INR 1,400 crore.
- Advanced discussions are ongoing for over 7 additional opportunities valued at around INR 900 crore.
- The CDMO contracts have visibility for the first few months and shipments for a large agrochemical order are expected to start by mid-March FY '26.
2 more points from Jubilant Ingrevia Ltd's call on order book
Create a free account to keep reading this call
Jubilant Ingrevia Ltd — Quarterly revenue & net profit
Jubilant Ingrevia Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,051 | 1,057 | -0.6% | 1,121 | -6.2% |
| Operating profit (EBITDA) | 126 | 138 | -8.7% | 135 | -6.7% |
| Operating margin | 12% | 13% | -1 pp | 12% | 0 pp |
| Profit before tax | 65 | 96 | -32.3% | 93 | -30.1% |
| Net profit (PAT) | 47 | 69 | -31.9% | 69 | -31.9% |
| EPS (₹) | 2.94 | 4.36 | -32.6% | 4.36 | -32.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.4K Cr, net profit ₹111 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Ingrevia's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Neochem Bio (Q3 FY26)
Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and
- Thirumalai Chemicals (Q3 FY26)
Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran
- IVP (Q3 FY26)
Q3 FY26 Revenue from Operations: ₹144.97 crore . Key investor presentation takeaways from IVP's Q3 FY26 investor presentation — and how it ranks against sector
- Gujarat Alkalies (Q3 FY26)
3,144.48 Crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks agai
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jubilant Ingrevia Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jubilant Ingrevia Ltd Q3 FY26 results?
Specialty Chemicals volume growth has been double-digit over the past years, expected to continue. Specialty Chemicals segment aims for at least 20% CAGR EBITDA growth over a multi-year horizon, maintaining stable EBITDA margins around 25-26%.
What is Jubilant Ingrevia Ltd share price analysis?
Jubilant Ingrevia Ltd currently shows a neutral. The stock trades at a P/E of 36.9 with a market cap of ₹11,738 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Ingrevia Ltd planning capital expenditure?
Year-to-date capex of INR366 crore primarily spent on the upcoming CDMO agro plant at Bharuch and new multipurpose facility at Gajraula.
Keep Jubilant Ingrevia Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
